Boston Scientific Corporation vs Synchrony Financial — how do they compare? Boston Scientific Corporation trades at $51.07 (market cap $74.19B), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Boston Scientific Corporation is far larger — about 2.9× Synchrony Financial's market cap, and Synchrony Financial pays a 1.73% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SYF | |
|---|---|---|
Market Cap | $74.19B | $25.53B |
Sector | Health | Financials |
52-Week High | $108.14 | $88.47 |
52-Week Low | $42.63 | $63.78 |
Enterprise Value | $86.27B | — |
Dividend Yield | — | 1.73% |
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →